InMed Pharmaceuticals, Inc. (IN) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1112221,
    "name": "InMed Pharmaceuticals, Inc.",
    "stock_name": "InMed Pharmaceuticals, Inc.",
    "full_name": "InMed Pharmaceuticals, Inc.",
    "name_url": "stocks-analysis/inmed-pharmaceuticals-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "1.34",
    "chg": 0.02,
    "chgp": "1.52%",
    "dir": 1,
    "prev_price": "1.32",
    "mcapval": "4.30",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 2305,
    "indexname": "S&P 500",
    "isin": "CA4576376012",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "262.28 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/inmed-pharmaceuticals-inc-1112221-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is InMed Pharmaceuticals, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-inmed-pharmaceuticals-inc-technically-bullish-or-bearish-3547078",
        "imagepath": "",
        "date": "2025-09-20 19:46:35",
        "description": "As of 12 September 2025, the technical trend for InMed Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish signal from the daily moving averages and a bearish reading from the KST on the weekly timeframe. Although the MACD shows mildly bullish signals on both weekly and monthly charts, the overall trend remains bearish due to the prevailing bearish signals from Bollinger Bands and Dow Theory on the monthly timeframe. \n\nIn terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -50.21% compared to the S&P 500's 12.22%, and a one-year return of -57.6% versus 17.14% for the index...."
      },
      {
        "title": "Is InMed Pharmaceuticals, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-inmed-pharmaceuticals-inc-overvalued-or-undervalued-3543516",
        "imagepath": "",
        "date": "2025-09-20 18:21:29",
        "description": "As of 23 September 2022, the valuation grade for InMed Pharmaceuticals, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, given its negative P/E ratio and poor return metrics. Key ratios include a Price to Book Value of 0.49, an EV to EBIT of 0.10, and an EV to EBITDA of 0.11, all suggesting that the company is struggling to generate positive returns.\n\nInMed Pharmaceuticals is compared to peers such as Plus Therapeutics, Inc., which has a significantly worse EV to EBITDA ratio of -3.3801, indicating that InMed is somewhat better positioned despite both being classified as risky. However, the company's recent stock performance has been dismal, with a year-to-date return of -50.21% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that the stock is overvalued in the current market context...."
      }
    ],
    "total": 7,
    "sid": "1112221",
    "stock_news_url": "https://www.marketsmojo.com/news/inmed-pharmaceuticals-inc-1112221"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Is InMed Pharmaceuticals, Inc. technically bullish or bearish?

2025-09-20 19:46:35

As of 12 September 2025, the technical trend for InMed Pharmaceuticals, Inc. has changed from mildly bearish to bearish. The current stance is bearish, with key indicators supporting this view including a bearish signal from the daily moving averages and a bearish reading from the KST on the weekly timeframe. Although the MACD shows mildly bullish signals on both weekly and monthly charts, the overall trend remains bearish due to the prevailing bearish signals from Bollinger Bands and Dow Theory on the monthly timeframe. In terms of performance, the stock has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -50.21% compared to the S&P 500's 12.22%, and a one-year return of -57.6% versus 17.14% for the index....

Is InMed Pharmaceuticals, Inc. overvalued or undervalued?

2025-09-20 18:21:29

As of 23 September 2022, the valuation grade for InMed Pharmaceuticals, Inc. moved from does not qualify to risky, indicating a shift in perception regarding its financial health. The company appears to be overvalued, given its negative P/E ratio and poor return metrics. Key ratios include a Price to Book Value of 0.49, an EV to EBIT of 0.10, and an EV to EBITDA of 0.11, all suggesting that the company is struggling to generate positive returns. InMed Pharmaceuticals is compared to peers such as Plus Therapeutics, Inc., which has a significantly worse EV to EBITDA ratio of -3.3801, indicating that InMed is somewhat better positioned despite both being classified as risky. However, the company's recent stock performance has been dismal, with a year-to-date return of -50.21% compared to the S&P 500's positive return of 12.22%, reinforcing the notion that the stock is overvalued in the current market context....

View All News